首页> 外国专利> TARGET VALIDATION AND PROFILING OF THE RNA TARGETS OF SMALL MOLECULES

TARGET VALIDATION AND PROFILING OF THE RNA TARGETS OF SMALL MOLECULES

机译:小分子RNA靶标的目标验证和分析

摘要

A method for the precise cellular destruction of an oncogenic non-coding RNA with a RNA-binding small molecule conjugated with bleomycin A5 is described. The method affords reversal of phenotype. Bleomycin A5 was coupled to an RNA-binding molecule that selectively binds the microRNA-96 hairpin precursor (pri-miR-96). By coupling of bleomycin A5's free amine to the RNA-binding molecule, its affinity for binding to pri-miR-96 is >100-fold stronger than to DNA. The conjugate compound selectively cleaves pri-miR-96 in triple negative breast cancer (TNBC) cells. Selective cleavage of pri-miR-96 enhances expression of FOXO1 protein, a pro-apoptotic transcription factor that miR-96 silences, and triggers apoptosis in TNBC cells. No effects were observed in healthy breast epithelial cells. This method provides programmable control for targeting RNA through the selection of an RNA-binding molecule/bleomycin A5 conjugate and provides a facile method of mapping the cellular binding sites of an RNA-binding molecule.
机译:描述了一种具有与宿霉素A5缀合的RNA结合的小分子的致癌非编码RNA的精确细胞破坏的方法。该方法提供了逆转表型。 Bleomycin A5偶联至有选择性地结合MicroRNA-96发夹前体(PRI-MIR-96)的RNA结合分子。通过将BLEOMYCIN A5的游离胺与RNA结合分子偶联,其与PRI-miR-96结合的亲和力> 100倍比DNA更强。缀合物化合物在三重阴性乳腺癌(TNBC)细胞中选择性地切割PRI-miR-96。 Pri-miR-96的选择性切割增强FoxO1蛋白的表达,促凋亡转录因子,miR-96沉默,触发TNBC细胞中的细胞凋亡。在健康的乳腺上皮细胞中没有观察到任何效果。该方法通过选择RNA结合分子/ Bleomycin A5缀合物提供可编程控制,用于通过选择RNA结合分子/ Bleomycin A5缀合物,并提供映射RNA结合分子的细胞结合位点的容纳方法。

著录项

  • 公开/公告号US2021379188A1

    专利类型

  • 公开/公告日2021-12-09

    原文格式PDF

  • 申请/专利权人 THE SCRIPPS RESEARCH INSTITUTE;

    申请/专利号US201917284297

  • 发明设计人 MATTHEW D. DISNEY;

    申请日2019-09-26

  • 分类号A61K47/55;C12N15/11;A61K31/704;

  • 国家 US

  • 入库时间 2022-08-24 22:43:31

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号